The breast cancer condition center is a comprehensive resource for clinical news and expert insights on breast cancer. Read more at OncLive.
June 2nd 2025
Erika Hamilton, MD, discusses data for vepdegestrant vs fulvestrant in ER-positive, HER2-negative advanced breast cancer.
Patients with metastatic breast cancer with higher HER2 amplicon mRNA signatures prior to T-DXd therapy had better outcomes vs those with lower signatures.
June 1st 2025
Sacituzumab govitecan in combination with pembrolizumab led to pathologic complete responses in early-stage triple-negative breast cancer.
Ribociclib plus a nonsteroidal aromatase inhibitor improved iDFS, DDFS, RFS, and DRFS in HR+/HER2– early breast cancer.
Emergent ESR1-mutant, ER-positive, HER2-negative advanced breast cancer was best treated with camizestrant and continued CDK4/6 inhibition vs SOC therapy.
May 31st 2025
Ipatasertib plus fulvestrant extended PFS vs placebo plus fulvestrant in patients with ER-positive/HER2-negative metastatic breast cancer.
Patient-reported outcomes revealed that imulunestrant with or without abemaciclib was favored vs SOC in ER-positive, HER2-negative breast cancer.
PFS was improved when patients with ESR1-mutant ER-positive, HER2-negative advanced breast cancer received treatment with vepdegestrant vs fulvestrant.
Frontline sacituzumab govitecan plus pembrolizumab improved PFS vs chemotherapy plus pembrolizumab in PD-L1+ metastatic triple-negative breast cancer.
May 30th 2025
A high rate of patients with breast cancer and other solid tumors were rechallenged with trastuzumab deruxtecan after grade 1 interstitial lung disease.
May 26th 2025
A 2025 ASCO press briefing previewed key advances in breast and lung cancer, HER2 diagnostics, and GLP-1s’ link to reduced cancer risk.
May 23rd 2025
The EMA’s CHMP has recommended the approval of inavolisib plus palbociclib/fulvestrant in PIK3CA-mutated, ER-positive advanced breast cancer.
Barriers in utilizing remote collection of patient-reported outcomes persist, although it has been proven to be effective in breast cancer.
May 22nd 2025
Inavolisib plus palbociclib and fulvestrant improved OS in PIK3CA-mutant, HR-positive, HER2-negative, endocrine-resistant advanced breast cancer.
AI-assisted training of pathologists enhanced the accuracy of HER2 IHC scoring, potentially expanding eligibility for HER2-targeted treatments.
Multiple experts on artificial intelligence in cancer care discuss its ever-expanding role in several areas of oncology.
The FDA granted breakthrough device designation to EnVisio X1 for minimally invasive surgery in cancer care.
May 21st 2025
Alexis LeVee, MD, discusses ongoing phase 3 trials evaluating the first-line use of ADCs in both PD-L1–positive and –negative TNBC.
May 19th 2025
An exploratory ctDNA analysis from postMONARCH highlighted the benefit of abemaciclib plus fulvestrant across HR-positive breast cancer subgroups.
Final analysis of SGNTUC-019 showed a 41.9% ORR, an 80.6% DCR, and a 18.2-month DOR with tucatinib/trastuzumab in pretreated, HER2-mutated metastatic breast cancer.